

Draft Guidelines Address Pressure Ulcer Care

BY HEIDI SPLETE

ARLINGTON, VA. — The first international guidelines for the prevention and treatment of pressure ulcers are available for public comment, and a final version will be released in May, according to presenters at the National Pressure Ulcer Advisory Panel.

The international collaboration adds a new dimension to the guidelines,

NPUAP President Laura Edsberg, Ph.D., said in an interview. “We have expanded the level of evidence that we are sharing,” she said. The draft guidelines result from the joint effort between the NPUAP and the European Pressure Ulcer Advisory Panel, based in England.

The treatment and prevention of pressure ulcers has become a hot topic in wound care, because pressure ulcers are among the conditions that Medicare

considers preventable and soon will not reimburse hospitals for, if the wounds arise there.

The draft guidelines cover both prevention and treatment. The prevention section details what makes patients vulnerable to pressure ulcers, such as long-term contact with devices including nasal cannulae and tracheostomy plates. But the guidelines also emphasize preventive strategies, such as managing

patient nourishment and hydration.

Additional guidelines compare different types of wound dressings, including foam, alginate, and hydrogel. Protocols for cleaning and supporting pressure ulcers, and alternative healing strategies including hydrotherapy, ultrasound, and maggot therapy are addressed.

More information on the draft guidelines and how to comment on them is at the NPUAP Web site, www.npuap.org. ■

Ustekinumab Beats Etanercept For Psoriasis

SAN FRANCISCO — Ustekinumab outperformed etanercept for treatment of psoriasis in the first-ever large head-to-head comparison of the two biologics.

The 12-week phase III multicenter trial involved 903 patients with moderate to severe plaque psoriasis who were randomized to two doses of the interleukin-12/-23-blocker ustekinumab (Stelara) at either 45 mg or 90 mg or to the tumor necrosis factor-inhibitor etanercept (Enbrel) at 50 mg twice weekly.

Ustekinumab is marketed in Europe and Canada and is under review by the



A PASI 90 was achieved in 45% of patients on high-dose ustekinumab and in 23% of those on etanercept.

DR. PAPP

U.S. Food and Drug Administration.

The primary study end point was at least a 75% improvement compared with baseline in Psoriasis Area and Severity Index (PASI 75). This was achieved in 68% of patients on ustekinumab 45 mg and 74% on 90 mg, both significantly better than the 57% rate with etanercept, Dr. Kim A. Papp said at the annual meeting of the American Academy of Dermatology.

A PASI 90 was achieved in 45% of patients who received high-dose ustekinumab, in 36% of those on low-dose ustekinumab, and in 23% on etanercept. Again, the outcome difference was significant, noted Dr. Papp of Probit Medical Research, Waterloo, Ont.


Of patients in the ustekinumab 90 mg group, 71% were rated clear or having only minimal skin involvement at 12 weeks by Physician Global Assessment. This was the case in 65% of patients in the low-dose ustekinumab group and in 49% of those on etanercept, he reported.

The trial was supported by Centocor Inc., which discovered ustekinumab and will market it in the United States. Dr. Papp serves as a consultant to and advisory board member for Centocor.

—Bruce Jancin

Relax, we've got painful muscle spasm under control.

amrix[®]
Cyclobenzaprine HCl
Extended-Release Capsules



Once-daily **AMRIX**...the proven efficacy of cyclobenzaprine with low rates of somnolence.¹

AMRIX (Cyclobenzaprine Hydrochloride Extended-Release Capsules) is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion. *AMRIX* should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. *AMRIX* has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy.

AMRIX is contraindicated in patients who are hypersensitive to any of its components. *AMRIX* is contraindicated with concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. *AMRIX* may have life-threatening interactions with MAO inhibitors. *AMRIX* is contraindicated during the acute recovery phase of myocardial infarction; in patients with arrhythmias, heart block conduction disturbances, or congestive heart failure; or in patients with hyperthyroidism. *AMRIX* may enhance the effects of alcohol, barbiturates, and other CNS depressants. *AMRIX* should not be used in elderly patients or in patients with impaired hepatic function.

In clinical trials, the most commonly reported adverse reactions ($\geq 3\%$) with *AMRIX* were dry mouth, dizziness, fatigue, nausea, dyspepsia, and constipation.

Please see brief summary of full prescribing information on the following page.

Reference: 1. Data on file. Studies 1105 and 1106. Cephalon, Inc.; 2004.



©2008 Cephalon, Inc. All rights reserved. AMR139 May 2008 Printed in USA.
AMRIX is produced with Eurand Diffucaps[®] technology.

For more information about *AMRIX*, call Cephalon Medical Services at

1-800-896-5855 or visit www.AMRIX.com